pipobroman has been researched along with Hemorrhagic Thrombocythemia in 28 studies
Pipobroman: An antineoplastic agent that acts by alkylation.
pipobroman : An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications." | 8.90 | Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. ( Newberry, KJ; Sever, M; Verstovsek, S, 2014) |
| "Pipobroman (PB) was tested in a prospective efficacy trial in 24 previously untreated patients with essential thrombocythemia and followed up for a median of 47 months (range, 12-120)." | 7.67 | Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients. ( Bernasconi, C; Brusamolino, E; Canevari, A; Merante, S; Salvaneschi, L, 1984) |
| "Pipobroman (PB) is a neutral amide of piperazine with a chemical structure close to that of alkylating agents, although the exact mechanism of action of PB has not been demonstrated." | 6.42 | Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. ( Lazzarino, M; Passamonti, F, 2003) |
| "Acute myeloid leukaemia, myelofibrosis and solid tumours occurred in three, two and seven patients with a 10-year cumulative risk of 3%, 2% and 7% respectively." | 5.31 | Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. ( Astori, C; Baratè, C; Bernasconi, P; Brusamolino, E; Canevari, A; Cazzola, M; Corso, A; Lazzarino, M; Malabarba, L; Orlandi, E; Pascutto, C; Passamonti, F, 2002) |
| "Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications." | 4.90 | Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. ( Newberry, KJ; Sever, M; Verstovsek, S, 2014) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| "Pipobroman (PB) was tested in a prospective efficacy trial in 24 previously untreated patients with essential thrombocythemia and followed up for a median of 47 months (range, 12-120)." | 3.67 | Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients. ( Bernasconi, C; Brusamolino, E; Canevari, A; Merante, S; Salvaneschi, L, 1984) |
| "Pipobroman (PB) is a neutral amide of piperazine with a chemical structure close to that of alkylating agents, although the exact mechanism of action of PB has not been demonstrated." | 2.42 | Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. ( Lazzarino, M; Passamonti, F, 2003) |
| "The risk of major thrombosis is higher in ET patients aged more than 60 ys." | 2.39 | Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. ( Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ, 1996) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer, and melanoma) and controls (n = 1234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of MPN diagnosis, and MPN disease duration." | 1.51 | Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. ( Alvarez-Larran, A; Angona, A; Barbui, T; Beggiato, E; Benevolo, G; Bertolotti, L; Betti, S; Bonifacio, M; Cacciola, R; Carli, G; Carobbio, A; Casetti, IC; Cattaneo, D; De Stefano, V; Delaini, F; Di Veroli, A; Elli, EM; Erez, D; Finazzi, G; Fox, ML; Ghirardi, A; Gomez, M; Griesshammer, M; Guglielmelli, P; Iurlo, A; Lunghi, F; Marchetti, M; Masciulli, A; McMullin, MF; Palandri, F; Palova, M; Patriarca, A; Perez-Encinas, M; Recasens, V; Rumi, E; Scaffidi, L; Stephenson, C; Tieghi, A; Vannucchi, AM; Vianelli, N; Wille, K, 2019) |
| "Acute myeloid leukaemia, myelofibrosis and solid tumours occurred in three, two and seven patients with a 10-year cumulative risk of 3%, 2% and 7% respectively." | 1.31 | Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. ( Astori, C; Baratè, C; Bernasconi, P; Brusamolino, E; Canevari, A; Cazzola, M; Corso, A; Lazzarino, M; Malabarba, L; Orlandi, E; Pascutto, C; Passamonti, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (14.29) | 18.7374 |
| 1990's | 5 (17.86) | 18.2507 |
| 2000's | 15 (53.57) | 29.6817 |
| 2010's | 4 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tefferi, A | 3 |
| Barbui, T | 3 |
| Andriani, A | 1 |
| Elli, E | 1 |
| Trapè, G | 1 |
| Villivà, N | 1 |
| Fianchi, L | 1 |
| Di Veroli, A | 2 |
| Niscola, P | 1 |
| Centra, A | 1 |
| Anaclerico, B | 1 |
| Montanaro, G | 1 |
| Martini, V | 1 |
| Aroldi, A | 1 |
| Carmosino, I | 1 |
| Voso, MT | 1 |
| Breccia, M | 1 |
| Montanaro, M | 1 |
| Foà, R | 1 |
| Latagliata, R | 1 |
| Ghirardi, A | 1 |
| Masciulli, A | 1 |
| Carobbio, A | 1 |
| Palandri, F | 1 |
| Vianelli, N | 1 |
| De Stefano, V | 1 |
| Betti, S | 1 |
| Iurlo, A | 1 |
| Cattaneo, D | 1 |
| Delaini, F | 1 |
| Bonifacio, M | 1 |
| Scaffidi, L | 1 |
| Patriarca, A | 1 |
| Rumi, E | 2 |
| Casetti, IC | 1 |
| Stephenson, C | 1 |
| Guglielmelli, P | 1 |
| Elli, EM | 1 |
| Palova, M | 1 |
| Bertolotti, L | 1 |
| Erez, D | 1 |
| Gomez, M | 1 |
| Wille, K | 1 |
| Perez-Encinas, M | 1 |
| Lunghi, F | 1 |
| Angona, A | 1 |
| Fox, ML | 1 |
| Beggiato, E | 1 |
| Benevolo, G | 1 |
| Carli, G | 1 |
| Cacciola, R | 1 |
| McMullin, MF | 1 |
| Tieghi, A | 1 |
| Recasens, V | 1 |
| Marchetti, M | 1 |
| Griesshammer, M | 3 |
| Alvarez-Larran, A | 1 |
| Vannucchi, AM | 1 |
| Finazzi, G | 2 |
| Sever, M | 1 |
| Newberry, KJ | 1 |
| Verstovsek, S | 1 |
| Bernasconi, P | 3 |
| Boni, M | 2 |
| Cavigliano, PM | 1 |
| Calatroni, S | 2 |
| Brusamolino, E | 4 |
| Passamonti, F | 5 |
| Volpe, G | 1 |
| Pistorio, A | 1 |
| Giardini, I | 1 |
| Rocca, B | 1 |
| Caresana, M | 1 |
| Lazzarino, M | 5 |
| Bernasconi, C | 2 |
| Sironi, M | 1 |
| Bertola, G | 1 |
| Lodato, A | 1 |
| Spinelli, M | 1 |
| Sciariada, L | 1 |
| Langer, C | 1 |
| De Sanctis, V | 1 |
| Mazzucconi, MG | 2 |
| Spadea, A | 1 |
| Alfò, M | 1 |
| Mancini, M | 1 |
| Bizzoni, L | 1 |
| Peraino, M | 1 |
| Mandelli, F | 2 |
| Malabarba, L | 2 |
| Arcaini, L | 1 |
| Orlandi, E | 3 |
| Pascutto, C | 2 |
| Cazzola, M | 3 |
| Kiladjian, JJ | 2 |
| Rain, JD | 1 |
| Bernard, JF | 1 |
| Briere, J | 3 |
| Chomienne, C | 1 |
| Fenaux, P | 2 |
| Reilly, JT | 1 |
| Canevari, A | 2 |
| Salvaneschi, L | 1 |
| Merante, S | 1 |
| Fuse, I | 1 |
| Dupuy, E | 1 |
| Randi, ML | 2 |
| Fabris, F | 2 |
| Girolami, A | 2 |
| Silverstein, MN | 1 |
| Guilmin, F | 1 |
| Bangerter, M | 1 |
| Grünewald, M | 1 |
| Triffet, A | 1 |
| Straetmans, N | 1 |
| Ferrant, A | 1 |
| Astori, C | 1 |
| Baratè, C | 1 |
| Corso, A | 1 |
| Bauters, F | 1 |
| Jouet, JP | 1 |
| Simon, M | 1 |
| Pollet, JP | 1 |
| Walter, MP | 1 |
| Francesconi, M | 1 |
| Chistolini, A | 1 |
| Falcione, E | 1 |
| Ferrari, A | 1 |
| Tirindelli, MC | 1 |
| Jamshidi, K | 1 |
| Ansari, A | 1 |
| Windschitl, HE | 1 |
| Swaim, WR | 1 |
9 reviews available for pipobroman and Hemorrhagic Thrombocythemia
| Article | Year |
|---|---|
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
Topics: Antineoplastic Agents; Busulfan; Disease Management; Drug Resistance; Histone Deacetylase Inhibitors | 2014 |
Pharmacotherapy of essential thrombocythaemia: economic considerations.
Topics: Age Factors; Antineoplastic Agents; Aspirin; Clinical Trials, Phase II as Topic; Cost-Benefit Analys | 2003 |
Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
Topics: Abortion, Spontaneous; Acute Disease; Alkylating Agents; Female; Humans; Leukemia, Myeloid; Middle A | 2003 |
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Topics: Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interfero | 2006 |
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; B | 1996 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
Management of patients with essential thrombocythemia: current concepts and perspectives.
Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Pr | 2001 |
Current treatment practice for essential thrombocythaemia in adults.
Topics: Adult; Aspirin; Humans; Hydroxyurea; Interferon-alpha; Pipobroman; Prognosis; Quinazolines; Thromboc | 2001 |
Bone marrow aplasia after pipobroman: an immune-mediated mechanism?
Topics: Aged; Aged, 80 and over; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Chronic Disease; Cyclo | 2001 |
19 other studies available for pipobroman and Hemorrhagic Thrombocythemia
| Article | Year |
|---|---|
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Female; Humans; Hydroxyurea; Leuke | 2019 |
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
Topics: Antineoplastic Agents; Case-Control Studies; Humans; Hydroxyurea; Neoplasms, Second Primary; Nitrile | 2019 |
Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Female; Humans; H | 2002 |
Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Humans; Hydroxyurea; Leukemia | 2003 |
Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution.
Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Disease Progression; Female; Humans; Leukemia; Ma | 2003 |
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.
Topics: Adult; Cause of Death; Drug Evaluation; Female; Humans; Incidence; Leukemia; Longitudinal Studies; M | 2004 |
Cytogenetic response to pipobroman in Philadelphia-positive chronic myeloid leukemia with thrombocythemic onset.
Topics: Aged; Antineoplastic Agents, Alkylating; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Hum | 2005 |
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
Topics: Adult; Humans; Hydroxyurea; Middle Aged; Pipobroman; Platelet Aggregation Inhibitors; Prognosis; Ris | 2004 |
Practical approach to treating essential thrombocythaemia: case studies.
Topics: Adult; Aspirin; Disease Management; Female; Humans; Hydroxyurea; Interferon-alpha; Leg Ulcer; Male; | 2007 |
Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients.
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Male; Middle Aged; Pipobroman; Polycythemia Vera; Pros | 1984 |
[Recent trends in therapy of chronic myeloproliferative disorders].
Topics: Alkylating Agents; Aspirin; Humans; Hydroxyurea; Interferons; Pipobroman; Prognosis; Thrombocythemia | 1993 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr | 1998 |
Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Busulfan; Female; Follow-Up Studies; Humans; | 1999 |
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Fatal Outcome; Female; Humans; Hydro | 2000 |
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle A | 2002 |
[Efficacy of pipobroman in the treatment of essential thrombocythemia].
Topics: Adult; Female; Humans; Pipobroman; Thrombocythemia, Essential | 1988 |
Pipobroman therapy of essential thrombocythemia.
Topics: Adult; Aged; Dipyridamole; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Hu | 1986 |
Primary thrombocythemia.
Topics: Adult; Aged; Blood Coagulation Tests; Bone Marrow Examination; Busulfan; Follow-Up Studies; Gastroin | 1973 |